Semax vs Selank: differences, evidence and safety

Answer first

Semax and Selank are both seven-link peptides from Moscow, given as nasal drops and licensed only in Russia. Semax copies a fragment of the stress hormone ACTH and is prescription-only there. Selank copies the immune peptide tuftsin and is sold without a prescription. Neither has a registered clinical trial, and no human study comparing their effects on symptoms was found.

At a glance

How they work

Both molecules are chains of seven amino acids, and both end in the same three links: proline, glycine and proline. That tail was added on purpose, because it slows the enzymes that break peptides apart ^[1], ^[2]. Everything in front of the tail is different.

Semax takes its first four links from a fragment of ACTH, the pituitary hormone that tells the adrenal glands to make steroid hormones ^[1].

• In side-by-side laboratory comparisons, ACTH fragments made adrenal cells produce steroids, while Semax did not. Its Russian product information describes it as completely without hormone activity ^[3].
• The FDA review of May 2026 states that Semax acts through poorly understood mechanisms and that no molecular target has been identified ^[1].
• The most reproduced laboratory finding is a rise in two nerve growth factors, BDNF and NGF, in rat brain tissue. No study showing it in a person could be found ^[4], ^[5], ^[6].
• In mice, Semax increased amphetamine-driven dopamine release, a pattern the FDA calls concerning because it resembles drugs of abuse ^[1].

Selank takes its first four links from tuftsin, a small immune peptide that the body cuts out of an antibody, immunoglobulin G ^[2].

• In human serum, Selank held back the enzymes that destroy enkephalins, the body's own opioid-like peptides. Half of that enzyme activity was blocked at 20 micromoles per litre ^[7], ^[8].
• In a binding study on brain cell membranes, it behaved as a positive allosteric modulator at the GABA receptor. Put simply, it may make the brain's main calming signal work better without sitting on the receptor itself ^[9].
• An hour after a dose, 45 of 84 nerve-signalling genes had changed their activity in the rat frontal cortex ^[10].
• Selank falls apart quickly. One fragment, glycine-proline, reproduced much the same gene-activity pattern in mouse spleen as the whole molecule ^[11], ^[12].

The core difference is the parent molecule: a stress hormone fragment for Semax, an antibody fragment for Selank. Russian law reflects this. It classes Semax as a nootropic, meant to act on mental performance. Selank is classed as an anxiolytic, meant to reduce anxiety ^[13], ^[14].

For both, every mechanism above comes from test tubes or animals, not from people.

What the studies show

Studies that tested both peptides

Head-to-head, brain imaging One human study included both peptides. In 2020, researchers scanned the brains of 52 healthy people, comparing Semax, Selank and a dummy treatment. Scans were taken before a dose and again 5 and 20 minutes afterwards ^[15].

The study found differences in how strongly the right amygdala, a brain region involved in fear, was coupled to nearby temporal regions ^[15]. It measured brain images, not symptoms. The participants were healthy, the paper runs to three pages, and nothing was registered ^[15]. It does not show that either peptide changes anxiety, memory or attention.

Head-to-head, animal In a 2017 rat model of Parkinson's disease, neither Semax nor Selank changed movement or avoidance learning. Selank only lowered the animals' anxiety ^[16]. This is a missed outcome for both peptides.

Head-to-head, laboratory A 2001 paper tested both peptides in human serum and reported that each inhibited the enzymes that break down enkephalins ^[7]. The figures quoted above come from the Selank work. This is a test-tube result, and nothing shows that a nasal dose reaches such concentrations in a person ^[7], ^[8].

Anxiety or focus?

This question comes up often, and the evidence behind it is thin on both sides. The Russian drug classes point one way: Selank is registered as an anxiolytic and Semax as a nootropic ^[13], ^[14].

Unregistered comparison, no dummy treatment For Selank, the anxiety evidence consists of three clinical comparisons against Russian sedatives, not against a dummy treatment. None describes blinding, and none appears in a trials register ^[17], ^[18], ^[19].

Unregistered, full text not obtainable For Semax, the attention evidence is one 1996 report. It states that a single nasal dose stimulated working memory and attention in 19 healthy men. The sample was small and male only, and the paper sits in a journal that PubMed does not index ^[1], ^[20].

The monographs behind this page report no human study that measured Semax against an anxiety scale, or Selank against a memory or attention test. So no comparison of the two peptides on either outcome could be found.

Selank: the clinical comparisons

Unregistered comparison, no dummy treatment A 2008 study gave 62 people with generalised anxiety disorder and neurasthenia either Selank (30) or the sedative medazepam (32). The paper reports comparable effects on the Hamilton and Zung anxiety scales. It is in Russian only ^[17].

Unregistered comparison, no dummy treatment A 2014 study compared Selank with phenazepam in 60 people with phobic anxiety and somatoform disorders. Phenazepam is a sedative approved only in Russia and a few neighbouring states. The paper reports a calming effect lasting a week beyond the last dose ^[18].

Unregistered comparison A 2015 study gave 70 people phenazepam alone (30) or phenazepam plus Selank (40). The combination is reported to have worked sooner and with fewer sedative side effects. The unequal groups argue against a proper one-to-one allocation ^[19].

Without a dummy arm, these designs cannot separate a genuine effect from the strong response that dummy treatments produce in anxiety ^[17], ^[18].

Semax: stroke, pain and a brain scan

Placebo-controlled imaging In 2018, 24 healthy adults were scanned, 14 after Semax and 10 after a dummy. The front part of one resting brain network, the default mode network, came out larger in the Semax group. No clinical outcome was measured ^[21].

The FDA notes that the Semax participants of this scan and the 2020 scan may well be the same people ^[1].

Open, uncontrolled A 1996 pain study covered 37 adults. Among 16 people with trigeminal neuralgia, a stabbing facial nerve pain, nothing changed at all. In 12 people with migraine the headache ended in 4 and eased in 8. The authors concluded that Semax shows no pain-relieving activity by itself ^[1], ^[22].

Observational, unregistered The Russian stroke studies form the largest body of human work. A 1997 study compared 30 patients given Semax with 80 on conventional treatment, without randomisation or blinding ^[23]. A 2005 report followed 187 patients with no described control group ^[24].

A 2018 study of 110 stroke patients in rehabilitation found higher blood levels of BDNF in the Semax groups. Those levels moved together with an everyday-function score, which is a correlation rather than proof of cause ^[25]. The FDA did not assess this literature, because no certified translation was supplied ^[1].

Animal work beyond the shared studies

Animal data Rats were given an experimental stroke. Eight days later, the area of dead brain tissue was around 20 percent smaller after Semax than after plain water ^[1]. The FDA notes that nearly all such studies used a single fixed dose level ^[1].

Animal data In rats in morphine withdrawal, Selank lowered the overall withdrawal score by 39.6 per cent. The sedative diazepam, tested alongside, lowered it by 49.3 per cent ^[26]. In mice, Selank calmed an anxious strain but not a placid one ^[27].

How far the numbers can be compared

The studies above differ in population, dose, outcome, route and length. Some enrolled patients, some healthy volunteers, some rats. Their numbers cannot be set against each other to rank the two peptides. Neither peptide has a registered clinical trial on ClinicalTrials.gov ^[28], ^[29].

Safety

Both peptides combine a licensed Russian product with an almost empty research file on safety. A short side-effect list on a label is not evidence of safety when the underlying testing was never published.

Semax

• One listed side effect. The Russian product information names mild irritation of the nasal lining with prolonged use, without a frequency ^[13].
• Who must not use it, per the label. People with hypersensitivity, acute psychotic states, anxiety conditions or a seizure history. Pregnancy and breastfeeding are also excluded ^[3], ^[13].
• One US report. Through 3 December 2025 the FDA adverse event database held one report. It described eye pain and burning after nasal drops bought online ^[1].
• Possible bleeding risk. Rat studies found increased clot-dissolving activity, from which the FDA draws a bleeding risk, particularly alongside blood-thinning medicines ^[1].
• No standard safety studies. No single-dose, repeated-dose, genetic-damage or reproductive study has been published, and immune reactions were never tested ^[1].

Selank

• Two listed side effects. Allergic reactions, including delayed ones, and an unpleasant taste when the liquid reaches the throat. Both are entered as frequency not known ^[14].
• A preservative that can cause allergy. The drops contain methyl 4-hydroxybenzoate, which the label says can itself cause allergic reactions ^[14].
• Who must not use it, per the label. People sensitive to any ingredient, pregnant or breastfeeding women, and anyone under 18. The stated reason is missing studies, not demonstrated harm ^[14].
• Slower clotting in rats. Selank shifted every clotting measure towards slower clotting in rats. The label does not mention this ^[30].
• Immune reactions. The FDA warns that selank acetate preparations may pose a risk of immune reactions for certain routes ^[31].
• Almost no toxicology. The only laboratory safety study found is a cell test on mouse embryonic stem cells ^[32].

How the body handles either peptide is largely unknown. For Semax, no human study of uptake and breakdown exists for any route ^[1]. For Selank, the label gives a nasal uptake of 92.8 per cent and a fall in blood levels over 5 to 5.5 minutes. No publication stands behind either figure ^[14].

Both approved routes are nasal. Injectable preparations circulate, with no human data for either peptide ^[1], ^[33].

Why this page lists no doses. Both peptides are licensed medicines in Russia. There, dosing belongs to the approved label and to the doctor or pharmacist. Outside Russia there is no approved product and no verifiable human study of how the body handles either peptide. So there is no defensible dose to report.

Legal status

Semax has been registered in Russia since 1994, on prescription only since 2003 ^[34]. Selank has been registered there since April 2009, without a prescription ^[35]. Neither is approved in the United States, the European Union, Germany, the United Kingdom, Australia, Canada or Switzerland. Both sit on the FDA list of bulk substances that may present significant safety risks ^[31]. In July 2026 an FDA advisory committee voted 8 to 5 to support compounding Semax; the vote is not binding ^[36], ^[37]. Neither peptide is named on the 2026 prohibited list, and clause S0 may not apply ^[38], ^[39]. See peptides banned in sport. Facts as checked on 6 September 2026.

Used together?

The myPeptides blend directory lists a product called Selank + Semax. Its entry describes a combination of the tuftsin analogue Selank with the ACTH (4-10) fragment Semax. It notes that both are registered as medicines only in Russia.

The FDA describes American wellness clinics and online sellers offering Semax alone and as a fixed combination with Selank. Both forms are sold as an injection and as a nasal spray ^[40]. No study of the combination sold in the United States could be found ^[1], ^[31].

The only effect studies that involved both peptides tested them separately within one experiment. These are the 2001 enzyme work, the 2020 brain scan and the 2017 rat study ^[7], ^[15], ^[16]. None of them gave the two together.

The directory also lists a blend called Neuroxelin. It contains N-acetyl Semax amidate and N-acetyl Selank amidate, which are not the same substances as Semax and Selank ^[41], ^[42]. The Russian medicines contain neither; the Selank drops hold the plain peptide as a diacetate salt ^[14], ^[42].

Frequently asked questions

Which is better, Semax or Selank?

No study answers that. No study in people comparing the two on a symptom or a clinical outcome could be found. The only human study with both, a 2020 brain scan of 52 healthy people, measured brain coupling rather than anything a person would notice. Each peptide's own studies used different people, outcomes and designs, so their results cannot be ranked.

Is Semax or Selank safer?

That cannot be said from the published record. The Semax label lists one side effect and the Selank label two, none with a frequency. Neither has published standard safety testing, and animal work flagged effects on blood clotting for both. Short lists reflect missing data, not proven safety.

What is the difference between Semax and Selank?

They come from different parent molecules. Semax copies a fragment of the stress hormone ACTH, while Selank copies tuftsin, an immune peptide cut from an antibody. They share only a stabilising three-link tail. In Russia, Semax is a prescription nootropic and Selank an over-the-counter anxiolytic.

Can Semax and Selank be taken together?

No study of the combination could be found. The research that involved both peptides tested them separately within the same experiment, never as a mixture. The myPeptides blend directory lists a product called Selank + Semax, and the FDA notes such combinations are sold in the United States. This page gives no guidance on use.

Is Selank for anxiety and Semax for focus?

That is how the Russian drug classes divide them: Selank is registered as an anxiolytic and Semax as a nootropic. The evidence behind each label is thin. Selank's anxiety studies compared it with sedatives, without a dummy treatment or described blinding. Semax's attention claim rests on one 1996 report in 19 healthy men.

Do you need a prescription for Semax or Selank in Russia?

For Semax, yes. It was first registered in 1994 without a prescription requirement, but every registration since 2003 has been prescription only. Selank has been registered since the end of April 2009 for supply without a prescription. Outside Russia, neither is an approved medicine.

Are Semax and Selank banned in sport?

Their status is unresolved. Neither is named on the 2026 prohibited list, and the catch-all clause for unapproved substances may not apply, because Russia's approvals are current. A 2025 review from within the anti-doping system places Semax in its unclear category. Athletes need a binding ruling from their own anti-doping organisation.

Are N-acetyl Semax amidate and N-acetyl Selank amidate the same as Semax and Selank?

No. N-acetyl Semax amidate is a chemically altered derivative, and the change measurably alters how the molecule binds copper and zinc. For N-acetyl Selank amidate, no record exists in PubChem, and none of the 77 genuine Selank papers describes such a variant. The Russian medicines contain neither.